Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven D Gore

Showing results (111-120 of 215) with videos related to

Pageof 22
Sort By:
European Journal of Haematology|April 17, 2010
Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*Valeria Santini, Pierre Fenaux, Ghulam J Mufti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2011
Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemiaGuillermo Garcia-Manero, Steven D Gore, Christopher Cogle, et al.
Annals of Hematology|July 30, 2016
Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemiaTae Kon Kim, Mina L Xu, Nikolai A Podoltsev, et al.
Cancer|September 5, 2019
Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population-level analysisAmer M Zeidan, Nikolai A Podoltsev, Xiaoyi Wang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 18, 2011
Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institutionAmy E DeZern, Anthony Sung, Sharon Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemiaJudith E Karp, B Douglas Smith, Mark J Levis, et al.
Epigenetics|July 31, 2010
Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemiaElizabeth A Griffiths, Steven D Gore, Craig M Hooker, et al.
Blood|June 15, 2007
A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemiasJudith E Karp, Rebecca M Ricklis, Kumudha Balakrishnan, et al.
Leukemia & Lymphoma|August 28, 2010
Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylationElizabeth A Griffiths, Steven D Gore, Craig Hooker, et al.
Haematologica|April 16, 2013
A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trialSteven D Gore, Pierre Fenaux, Valeria Santini, et al.
Pageof 22

Showing results (111-120 of 215) with videos related to

Sort By:
Pageof 22
European Journal of Haematology|April 17, 2010
Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*Valeria Santini, Pierre Fenaux, Ghulam J Mufti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2011
Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemiaGuillermo Garcia-Manero, Steven D Gore, Christopher Cogle, et al.
Annals of Hematology|July 30, 2016
Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemiaTae Kon Kim, Mina L Xu, Nikolai A Podoltsev, et al.
Cancer|September 5, 2019
Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population-level analysisAmer M Zeidan, Nikolai A Podoltsev, Xiaoyi Wang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 18, 2011
Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institutionAmy E DeZern, Anthony Sung, Sharon Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemiaJudith E Karp, B Douglas Smith, Mark J Levis, et al.
Epigenetics|July 31, 2010
Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemiaElizabeth A Griffiths, Steven D Gore, Craig M Hooker, et al.
Blood|June 15, 2007
A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemiasJudith E Karp, Rebecca M Ricklis, Kumudha Balakrishnan, et al.
Leukemia & Lymphoma|August 28, 2010
Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylationElizabeth A Griffiths, Steven D Gore, Craig Hooker, et al.
Haematologica|April 16, 2013
A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trialSteven D Gore, Pierre Fenaux, Valeria Santini, et al.
Pageof 22